HLA-C and neuroblastoma: While CAR T cells and checkpoint inhibitors have been successful in other pediatric and adult malignancies, these approaches in NB are severely limited,17 in part due to low expression of major histocompatibility complex (MHC) molecules, low mutational burden in NB, and severe side effects, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.18